Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.47
−$0.05 · -3.29%
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Regular session
$1.47
−$0.05 · -3.29%
Regular session · ET · Market data may be delayed.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Day range
Current $1.47
52-week range
Current $1.47
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
45
Fair Value
Sentiment
66
Bullish
Risk
70
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Day range
Current $1.47
52-week range
Current $1.47
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 200.86K USD | 337.49K USD | 408.03K USD | 435.2K USD | 681.61K USD |
| Gross profit | −200.86K USD | −337.49K USD | −408.03K USD | −435.2K USD | −681.61K USD |
| Research and development | 2.78M USD | 2.84M USD | 7.25M USD | 8.03M USD | 4.79M USD |
| Selling, general, and administrative | 5.79M USD | 6.45M USD | 8.79M USD | 11.5M USD | 20.47M USD |
| Operating expenses | 8.57M USD | 9.29M USD | 16.04M USD | 19.53M USD | 25.26M USD |
| Interest income | — | 219 USD | — | 5.25 USD | 10.32 USD |
| Interest expense | 106 USD | — | 3.71K USD | 5.25K USD | 10.32K USD |
| Depreciation and amortization | 200.86K USD | 337.49K USD | 408.03K USD | 435.2K USD | 681.61K USD |
| Operating income | −8.77M USD | −9.63M USD | −16.45M USD | −19.96M USD | −25.94M USD |
| Net income | −12.13M USD | −9.57M USD | −17.29K USD | −18.5M USD | −48.98M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Apr 23, 2008 | $0.021Irregular | Apr 15, 2008 | — |
Ex-dividend Apr 23, 2008
$0.021
Irregular
Record Apr 15, 2008
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
